pHalcon‑NERD: a phase 3 study of VOQUEZNA in Non‑Erosive GERD1,2
The efficacy and safety of VOQUEZNA 10 mg vs placebo was evaluated in a phase 3, randomized, double‑blind, multicenter, 4‑week study conducted in the US in patients with heartburn related to Non‑Erosive GERD. The study also included a 20‑week exploratory extension period evaluating the treatment effect of VOQUEZNA 10 mg (no placebo).1,2
STUDY DESIGN
*Represents ITT population.
†A higher dose treatment group not shown, although this group is included in the total number of randomized patients.1
‡Extension period was an exploratory endpoint not tested for statistical significance.2